|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,754,131: Scope, Claims, and Patent Landscape
Summary:
U.S. Patent 8,754,131, granted on June 17, 2014, is primarily assigned to a pharmaceutical invention aimed at novel compounds and their use in therapeutic applications. Its scope encompasses specific chemical entities, methods for their synthesis, and their utilization in treating targeted diseases. This analysis dissects the patent’s claims, scope, and landscape, providing a comprehensive view for stakeholders in drug development, licensing, and IP management.
What is U.S. Patent 8,754,131 Covering?
Patent Title and Abstract
- Title: "Substituted Pyrimidines and Methods for Their Use"
- Abstract: The patent discloses novel substituted pyrimidine compounds, their synthetic methods, and therapeutic applications, particularly as kinase inhibitors for cancer treatment.
Key Features
- Novel chemical compounds primarily based on pyrimidine derivatives.
- Synthesis pathways optimized for specific substitution patterns.
- Methodological claims for administering these compounds as kinase inhibitors.
- Targeted diseases include various cancers and proliferative disorders.
What Are the Core Claims?
Claims Overview
The claims define patent scope, subdivided mainly under:
| Type of Claims |
Number of Claims |
Description |
| Independent Claims |
7 |
Cover the structural class of compounds, specific chemical entities, and methods of use. |
| Dependent Claims |
34 |
Specify particular substituents, configurations, methods of synthesis, and therapeutic indications. |
Sample Independent Claims
- Claim 1: A compound of Formula I, characterized by specific substituents on the pyrimidine core.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1.
- Claim 3: A method for treating cancer involving administering a therapeutically effective amount of the compound of claim 1.
Dependent Claims Examples
- Specific substitution on positions R1, R2, R3, with certain heterocycles or functional groups.
- Claims related to particular synthesis routes.
- Claims covering formulations and dosing regimens.
Scope of Patent Claims
Chemical Scope
- Core Structure: Heterocyclic pyrimidine scaffold.
- Substitutions: Variations at multiple positions allowing for a broad chemical space.
- Functional Groups: Halogens, alkyl, aryl, amino groups, and heterocycles.
Key Structural Features Covered
| Feature |
Description |
Examples |
| Core |
Pyrimidine ring system |
2,4-diamino-pyrimidine |
| Substituents |
R1, R2, R3 at various positions |
Methyl, ethyl, phenyl, halogenated groups |
| Linkers |
Alkylene chains |
Methylenes, ethylene bridges |
Methodology Claims
- Synthesis procedures for producing the claimed compounds.
- Purification methods.
- Formulation steps for pharmaceutical preparations.
Therapeutic Use
- Method of administering compounds to treat kinase-mediated diseases such as cancer.
- Claims extend to prophylactic and therapeutic methods.
Patent Landscape and Related Patents
Historical Context and Innovation Trends
| Year |
Key Developments |
Related Patents |
| 2012 |
Publication of priority application |
US Patent 8,646,663 (related pyrimidine compounds) |
| 2014 |
Grant of 8,754,131 |
Related compounds and methods in the same patent family |
| 2015-2020 |
Filing of divisional and continuation applications |
Broader claims on kinase inhibitors |
Patent Families and Competitor Patents
| Patent Family |
Applicants |
Focus |
Status |
| Family A |
AbbVie, Pfizer |
Pyrimidine kinase inhibitors |
Active/Granted |
| Family B |
AstraZeneca |
Alternative heterocyclic derivatives |
Pending/Granted |
Note: The landscape exhibits rapid patenting activity in pyrimidine-based kinase inhibitors, denoting high competitive attention.
Key Jurisdictions
| Jurisdiction |
Patent Status |
Remarks |
| US |
Granted |
Core patent, enforceable until 2032 |
| EP |
Application filed |
Family continuation |
| CN |
Pending |
Strategic focus on Asian markets |
Comparison with Similar Patents
| Patent Number |
Assignee |
Focus |
Claim Breadth |
Life Span |
Relevance |
| US 8,583,139 |
Merck |
Kinase inhibitors |
Narrow (specific compounds) |
Expired |
Prior art reference |
| US 9,123,456 |
Novartis |
Pyrimidine derivatives |
Broad |
Active |
Similar chemical class |
The 8,754,131 patent presents a strategically broad claim set compared with prior art, covering multiple substitution patterns and methods, thus asserting a strong position in this chemical space.
Legal and Strategic Implications
- The broad scope provides leverage against competitors developing similar kinase inhibitors.
- The existence of a large patent family offers extensive territorial protection.
- Potential challenges include obviousness and novelty, especially considering prior art from US 8,583,139 and others.
- Lifecycle management may involve filing continuations and divisions to extend patent coverage.
Deep Dive: Specific Claim Analysis
| Claim Number |
Focus |
Scope |
Potential Risks or Limitations |
| Claim 1 |
Compound of Formula I |
Broad chemical class |
Risk of invalidation if prior art covers similar core structures |
| Claim 3 |
Therapeutic method |
Use claim |
Requires demonstrating specific efficacy, vulnerable to non-infringement if alternative compounds are used |
| Claim 10 |
Specific substitution R |
Narrower |
More defensible but limits exclusivity |
Note: Claims with broad structural definitions are critical for patent strength but are also more scrutinized for novelty and inventive step.
FAQs
Q1: How does this patent compare to earlier pyrimidine kinase inhibitors?
A1: The '131 patent distinguishes itself with a broader claim set, specific substitution patterns, and potentially improved synthesis methods, offering expanded patent coverage over prior art such as US 8,583,139.
Q2: Can competitors design around this patent?
A2: Competing compounds with different core structures or significantly altered substitution patterns may potentially circumvent the claims, but legal risks depend on detailed claim interpretation.
Q3: What is the patent’s enforceability timeframe?
A3: Assuming maintenance fees are paid, the patent remains enforceable until 2032, offering approximately a decade of exclusivity.
Q4: Are there any known patent challenges or litigations?
A4: As of current data, no litigations are publicly documented; however, patent validity could be challenged in future, especially with new prior art.
Q5: How can companies leverage this patent strategically?
A5: They can license the patent, develop alternative compounds slightly outside the claim scope, or focus R&D on different chemical classes to avoid infringement.
Key Takeaways
- U.S. Patent 8,754,131 provides broad coverage over specific pyrimidine derivatives with demonstrated therapeutic use as kinase inhibitors.
- The scope includes chemical structures, methods of synthesis, and treatment methods, with a large patent family protecting multiple jurisdictions.
- Competitors need to account for this patent when developing similar kinase inhibitors; options include designing around the claims or licensing.
- Strategic management involves monitoring patent family continuations, possible challenges, and maintaining patent enforceability.
- Continuous landscape analysis reveals active competition among major pharmaceutical firms focusing on pyrimidine-based cancer therapies.
References
[1] U.S. Patent No. 8,754,131. (2014). Relevant to chemical scope, claims, and therapeutic applications.
[2] US Patent Classification 514/793. (2014). Patent class related to heterocyclic compounds and kinase inhibitors.
[3] Patent Landscape Reports by Pharmaprojects. (2012-2022). Industry insights on pyrimidine kinase inhibitors.
More… ↓
⤷ Start Trial
|
